A patient with atrial fibrillation and CKD stage 4 (eGFR 22 mL/min) requires anticoagulation. Which DOAC is safest and why?

• A Rivaroxaban; it has the lowest renal clearance among factor Xa inhibitors
• B Apixaban; approximately 27% is eliminated renally (lowest renal contribution among DOACs), making it safest in severe CKD — dose adjustment (2.5 mg BD) is used with two of three criteria met (age ≥80, weight ≤60 kg, SCr ≥1.5 mg/dL) ✓
• C Dabigatran; provides most predictable anticoagulation as it requires no renal dose adjustment
• D Edoxaban; only DOAC approved for eGFR <30 mL/min

Explanation

Among DOACs, dabigatran is 80% renally cleared (contraindicated in severe CKD); edoxaban is ~50% renally cleared; rivaroxaban ~33%; apixaban ~27%. Apixaban has the lowest dependence on renal elimination and can be used cautiously in advanced CKD (eGFR 15–29 mL/min) with dose reduction (5 mg BD → 2.5 mg BD when 2/3 criteria met). It has the largest body of evidence in CKD. Option C is incorrect as dabigatran is most renal-dependent; option D is incorrect as edoxaban is actually cautioned with very low eGFR (paradoxically, edoxaban is also contraindicated when eGFR >95 mL/min due to reduced efficacy).

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.